Suppliers and packagers for CHLORAMPHENICOL SODIUM SUCCINATE

CHLORAMPHENICOL SODIUM SUCCINATE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Fresenius Kabi Usa	CHLORAMPHENICOL SODIUM SUCCINATE	chloramphenicol sodium succinate	INJECTABLE;INJECTION	062365	ANDA	Fresenius Kabi USA, LLC	63323-011-15	10 VIAL in 1 TRAY (63323-011-15) / 10 mL in 1 VIAL	2001-01-12

Chloramphenicol Sodium Succinate Supply Chain Analysis

Last updated: February 19, 2026

This report analyzes the global supply chain for Chloramphenicol Sodium Succinate, a broad-spectrum antibiotic, focusing on key manufacturers, their production capacities, regulatory standing, and potential supply chain risks. The analysis is critical for R&D and investment decisions concerning this drug.

What is Chloramphenicol Sodium Succinate?

Chloramphenicol Sodium Succinate is an ester prodrug of chloramphenicol, a bacteriostatic antibiotic. It is administered intravenously and is hydrolyzed in vivo to release active chloramphenicol. This formulation is primarily used for severe infections where oral administration is not feasible or effective, such as typhoid fever, meningitis, and other serious Gram-negative bacterial infections. Its use is often reserved for situations where other antibiotics are ineffective or contraindicated due to potential side effects, primarily aplastic anemia.

Key Manufacturers and Their Capabilities

The production of Chloramphenicol Sodium Succinate involves complex chemical synthesis and stringent quality control to meet pharmaceutical standards. The global supply is concentrated among a limited number of manufacturers, primarily located in Asia.

Primary Active Pharmaceutical Ingredient (API) Manufacturers

Several companies manufacture the API for Chloramphenicol Sodium Succinate. These manufacturers are critical to the drug's availability.

• Aurobindo Pharma Ltd. (India): A significant global player in generic drug manufacturing. Aurobindo has a broad portfolio of APIs, including those for antibiotics. Their facilities are generally compliant with major regulatory bodies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Production capacity for Chloramphenicol Sodium Succinate is substantial, catering to both domestic and international markets.
• Laurus Labs Ltd. (India): Another prominent Indian API manufacturer with a strong focus on complex chemistries. Laurus Labs is known for its robust R&D capabilities and high-quality manufacturing standards. Their facilities are subject to regular inspections by global regulatory agencies. While specific production volumes for Chloramphenicol Sodium Succinate are not publicly disclosed, their overall API output suggests significant capacity.
• Sarthak Pharmaceuticals Pvt. Ltd. (India): A specialized manufacturer of pharmaceutical intermediates and APIs. Sarthak Pharmaceuticals focuses on niche products and has demonstrated consistent supply capabilities. Their regulatory compliance is typically maintained to serve regulated markets.
• Qilu Pharmaceutical Co., Ltd. (China): A major Chinese pharmaceutical company with extensive manufacturing facilities. Qilu Pharmaceutical produces a wide range of APIs and finished dosage forms. Their operations are geared towards large-scale production, and they adhere to Chinese Good Manufacturing Practices (GMP) and often seek international certifications.
• Hunan Xinhua Pharmaceutical Co., Ltd. (China): A long-standing pharmaceutical company in China with a history of producing essential medicines, including antibiotics. Hunan Xinhua possesses significant manufacturing infrastructure and is a key supplier in the Asian market and for export.

Finished Dosage Form (FDF) Manufacturers

The final drug product, Chloramphenicol Sodium Succinate for injection, is manufactured by companies that source the API from primary manufacturers. These companies formulate, fill, and finish the product under sterile conditions.

• Pfizer Inc. (Global): While not a primary API producer for this specific niche, Pfizer has historically been involved in the distribution and marketing of chloramphenicol products. Their involvement in FDF manufacturing for specific markets or through partnerships would leverage their global regulatory expertise.
• Various Generic Manufacturers (India, China, and other regions): Numerous generic pharmaceutical companies worldwide produce Chloramphenicol Sodium Succinate injections. These include companies such as:
  • Fresenius Kabi (Germany): A global healthcare company specializing in infusion therapies, generic intravenous medicines, and medical devices. Fresenius Kabi's sterile injectable product lines are extensive and comply with stringent international standards.
  • VHB Life Sciences Ltd. (India): A growing Indian pharmaceutical company that focuses on injectables and other critical care products.
  • Beijing Union Pharmaceutical Factory (China): A significant Chinese manufacturer of sterile injectables.

Production Capacity and Scale

Estimating precise production capacities for Chloramphenicol Sodium Succinate API is challenging due to proprietary information. However, based on the scale of operations of the key manufacturers, particularly those in India and China, the global capacity is considered sufficient to meet current demand.

• India: Indian manufacturers are a dominant force in global API production due to cost-effectiveness, robust regulatory compliance (evidenced by a high number of FDA and EMA approved facilities), and established expertise in complex synthesis. Companies like Aurobindo and Laurus Labs have multi-tonne per annum capacities for various APIs, suggesting their Chloramphenicol Sodium Succinate production would align with this scale if prioritized.
• China: Chinese manufacturers, such as Qilu Pharmaceutical and Hunan Xinhua, also possess large-scale manufacturing capabilities. Their production is critical for the Asian market and significant for global exports.

The production of injectable FDFs requires specialized sterile manufacturing facilities. Companies like Fresenius Kabi operate multiple such facilities globally, enabling them to produce a wide range of sterile injectables, including Chloramphenicol Sodium Succinate, in volumes dictated by market demand and tender awards.

Regulatory Landscape and Compliance

The regulatory environment for pharmaceuticals, especially injectable drugs, is highly stringent. Compliance with Good Manufacturing Practices (GMP) is paramount.

• U.S. Food and Drug Administration (FDA): Manufacturers exporting to the United States must have FDA approval for their manufacturing facilities and API. This involves rigorous inspections to ensure quality, safety, and efficacy.
• European Medicines Agency (EMA): Similar to the FDA, the EMA sets strict standards for pharmaceuticals sold within the European Union. Facilities supplying to the EU undergo inspections and require Certificates of Suitability (CEP) for APIs from the European Directorate for the Quality of Medicines & HealthCare (EDQM).
• World Health Organization (WHO): WHO prequalification is crucial for suppliers seeking to participate in global procurement programs for essential medicines, especially in developing countries.
• National Regulatory Authorities: Each country has its own regulatory body (e.g., CDSCO in India, NMPA in China) that oversees drug manufacturing and approval within their borders.

Key Compliance Indicators for Chloramphenicol Sodium Succinate Manufacturers:

• FDA Audits: Successful recent FDA inspections of API manufacturing sites are a strong indicator of quality.
• EDQM CEPs: Certificates of Suitability issued by EDQM for the API.
• WHO Prequalification: For specific FDF formulations intended for global health initiatives.
• GMP Certifications: Demonstrating adherence to international GMP standards.

Table 1: Key Regulatory Approvals and Certifications

Manufacturer/Company Type	Key Markets Served	Primary Regulatory Focus	Typical Certifications
Aurobindo Pharma Ltd. (API)	Global (US, EU, ROW)	FDA, EMA, TGA, Health Canada	FDA Approved Site, EU GMP, WHO GMP, ISO 9001
Laurus Labs Ltd. (API)	Global (US, EU, ROW)	FDA, EMA, PMDA (Japan)	FDA Approved Site, EU GMP, PMDA Approved Site, ISO 14001
Sarthak Pharmaceuticals (API)	India, ROW	CDSCO (India), emerging market approvals	ISO 9001, adherence to ICH guidelines
Qilu Pharmaceutical Co., Ltd. (API)	China, Asia, ROW	NMPA (China), FDA (site inspections), EMA (site inspections)	GMP Compliance (China), adherence to international standards
Hunan Xinhua Pharmaceutical (API)	China, Asia, ROW	NMPA (China), WHO GMP	GMP Compliance (China), WHO GMP
Fresenius Kabi (FDF)	Global (US, EU, ROW)	FDA, EMA, TGA, Health Canada, WHO	FDA Approved FDF Site, EU GMP, WHO GMP, ISO 13485 (for medical devices)
VHB Life Sciences Ltd. (FDF)	India, Emerging Markets	CDSCO (India), WHO GMP	WHO GMP, ISO 9001
Beijing Union Pharmaceutical (FDF)	China, Asia	NMPA (China), WHO GMP	GMP Compliance (China), WHO GMP

(ROW: Rest of World; FDF: Finished Dosage Form; API: Active Pharmaceutical Ingredient; GMP: Good Manufacturing Practices; TGA: Therapeutic Goods Administration (Australia); PMDA: Pharmaceuticals and Medical Devices Agency (Japan); CDSCO: Central Drugs Standard Control Organisation (India); NMPA: National Medical Products Administration (China))

Supply Chain Risks and Considerations

The supply chain for Chloramphenicol Sodium Succinate is subject to several risks that could impact availability and pricing.

Raw Material Sourcing

The synthesis of Chloramphenicol Sodium Succinate relies on specific chemical precursors. Disruptions in the supply of these precursors, whether due to geopolitical instability, environmental regulations, or manufacturing issues at upstream suppliers, can affect the production of the final API. For example, the availability of key starting materials for the chloramphenicol molecule itself, such as p-nitroacetophenone, is critical.

Manufacturing Disruptions

• Facility Incidents: Fires, natural disasters, or accidents at manufacturing sites can lead to temporary or prolonged production shutdowns.
• Regulatory Actions: A facility failing a critical regulatory inspection (e.g., by the FDA or EMA) can result in import alerts, product recalls, or a complete halt in its ability to supply regulated markets.
• Labor Issues: Strikes or labor disputes at manufacturing facilities can impact production output.

Geopolitical and Trade Factors

• Trade Tariffs and Embargoes: Changes in international trade policies can affect the cost and availability of APIs and finished products.
• Regional Instability: Political instability in key manufacturing regions can disrupt logistics and production.
• Export Restrictions: Governments may impose export restrictions on critical medicines during public health emergencies or periods of high domestic demand.

Quality Control and Counterfeit Products

Maintaining consistent quality is paramount for injectables. Any lapse in quality control by an API or FDF manufacturer can lead to significant patient safety risks and regulatory actions. The potential for counterfeit products entering the supply chain, particularly in regions with weaker regulatory oversight, remains a persistent concern.

Dependence on Limited Suppliers

The concentration of API manufacturing among a few key players, particularly in India and China, creates a degree of dependence. If one or two major suppliers face significant production issues or withdraw from the market, it can lead to shortages.

Environmental, Social, and Governance (ESG) Factors

Increasingly, investors and regulators are scrutinizing the ESG practices of pharmaceutical manufacturers. Issues related to waste management, energy consumption, and labor practices can impact a company's reputation and operational stability.

Market Dynamics and Pricing

The market for Chloramphenicol Sodium Succinate is primarily driven by its use in specific, severe infections. As newer, often safer, broad-spectrum antibiotics have become available, the use of chloramphenicol has generally declined in developed countries, reserving it for specific indications like typhoid fever or when other treatments fail. However, it remains an essential medicine in many low- and middle-income countries where cost and availability are critical factors.

• Pricing: Pricing is influenced by API manufacturing costs, regulatory compliance investments, FDF formulation complexity, and market competition. Generic competition is significant, which tends to keep prices relatively low for established products. However, supply chain disruptions or increased raw material costs can lead to price volatility.
• Tenders and Procurement: A significant portion of Chloramphenicol Sodium Succinate FDF is procured through government tenders and international organizations like UNICEF and WHO for distribution in public health programs. This can lead to volume-based pricing agreements.

Future Outlook and Strategic Considerations

The demand for Chloramphenicol Sodium Succinate is expected to remain stable, driven by its continued role as an essential medicine for specific indications, particularly in regions with a high burden of infectious diseases. However, the long-term trend may see a gradual decline in its use in favor of newer, more targeted therapies with better safety profiles in developed markets.

For R&D and investment professionals, the following strategic considerations are relevant:

• Supplier Diversification: For FDF manufacturers or pharmaceutical companies relying on this drug, diversifying API suppliers across different geographical regions can mitigate single-source risk.
• Supply Chain Transparency: Gaining visibility into the entire supply chain, including upstream raw material suppliers, is crucial for proactive risk management.
• Regulatory Vigilance: Continuous monitoring of the regulatory compliance status of key suppliers is essential. Changes in GMP standards or new regulatory requirements can impact product availability and market access.
• Investment in Robust FDF Manufacturing: For companies involved in FDF production, investing in state-of-the-art sterile manufacturing facilities that meet global GMP standards is critical for ensuring product quality and market access.
• Monitoring Emerging Therapies: Staying abreast of the development of newer antibiotic classes that may eventually replace chloramphenicol in its key indications is important for long-term strategic planning.

Key Takeaways

• The global supply of Chloramphenicol Sodium Succinate API is primarily concentrated among manufacturers in India and China, with Aurobindo Pharma, Laurus Labs, Qilu Pharmaceutical, and Hunan Xinhua Pharmaceutical being key players.
• Finished Dosage Form (FDF) manufacturing is carried out by numerous generic companies, with global players like Fresenius Kabi also participating.
• Regulatory compliance, particularly with FDA and EMA standards, is a critical factor for market access in developed countries.
• Supply chain risks include raw material sourcing disruptions, manufacturing incidents, geopolitical factors, and the potential for counterfeit products.
• While a critical and essential medicine, the use of Chloramphenicol Sodium Succinate may decline in developed markets due to the availability of newer therapies, but it will likely remain important in low- and middle-income countries.

FAQs

What is the primary therapeutic use of Chloramphenicol Sodium Succinate?

Its primary therapeutic use is for the treatment of severe bacterial infections where other antibiotics are ineffective or contraindicated. This includes infections like typhoid fever, bacterial meningitis, and severe Gram-negative bacterial infections.

Which countries are the largest producers of Chloramphenicol Sodium Succinate API?

India and China are the largest producers of Chloramphenicol Sodium Succinate API, with significant contributions from companies like Aurobindo Pharma, Laurus Labs, Qilu Pharmaceutical, and Hunan Xinhua Pharmaceutical.

What are the main risks associated with the supply chain for this drug?

The main risks include disruptions in the supply of critical raw materials, manufacturing incidents, geopolitical instability, changes in trade policies, and the potential for counterfeit products to enter the market.

How do regulatory agencies like the FDA and EMA impact the supply of Chloramphenicol Sodium Succinate?

These agencies set stringent quality and manufacturing standards. Facilities supplying to the US and EU markets must undergo rigorous inspections and obtain approvals, which can limit the number of qualified suppliers and affect product availability and cost.

Is Chloramphenicol Sodium Succinate still widely used in developed countries?

Its use has generally declined in developed countries due to the availability of newer, more targeted antibiotics with improved safety profiles. It is often reserved for specific indications or when other treatments have failed.

What is the impact of generic competition on the pricing of Chloramphenicol Sodium Succinate?

Generic competition is significant for this drug, which tends to keep prices relatively low. However, factors such as API manufacturing costs, regulatory compliance expenses, and supply chain disruptions can influence price fluctuations.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Shortages. Retrieved from https://www.fda.gov/drugs/drug-shortages

[2] European Medicines Agency. (n.d.). Information on medicines. Retrieved from https://www.ema.europa.eu/en

[3] World Health Organization. (n.d.). Essential Medicines. Retrieved from https://www.who.int/news-room/questions-and-answers/item/essential-medicines

[4] Aurobindo Pharma Ltd. (2023). Annual Report 2022-23. Retrieved from Aurobindo Pharma Investor Relations.

[5] Laurus Labs Ltd. (2023). Annual Report 2022-23. Retrieved from Laurus Labs Investor Relations.

[6] Qilu Pharmaceutical Co., Ltd. (Information available through company website and industry reports).

[7] Hunan Xinhua Pharmaceutical Co., Ltd. (Information available through company website and industry reports).

[8] Fresenius Kabi. (Information available through company website and investor relations).

[9] Sarthak Pharmaceuticals Pvt. Ltd. (Information available through company website and industry directories).

[10] VHB Life Sciences Ltd. (Information available through company website and industry directories).

[11] Beijing Union Pharmaceutical Factory. (Information available through company website and industry reports).